Diligence memo · auto-generated · as of July 2, 2026

EdenRoc Sciences LLC

EdenRoc Sciences LLC looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

EdenRoc Sciences LLC operates in Biotechnology, based in Worcester.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

EdenRoc Sciences LLC has raised $212M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $64M on 2022-06-17.

Most recent recorded round closed around 2024-11-07.

Valuation (modeled)modeled

Provath models EdenRoc Sciences LLC at approximately $21M (range $8.5M–$31M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.04× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 8 months.

Last raise 20 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 20.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 97% of Biotechnology peers (4293 compared).

Modeled value ranks above 29% of those peers.

Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.